ZA975942B - Non-aqueous protic peptide formulations. - Google Patents

Non-aqueous protic peptide formulations.

Info

Publication number
ZA975942B
ZA975942B ZA9705942A ZA975942A ZA975942B ZA 975942 B ZA975942 B ZA 975942B ZA 9705942 A ZA9705942 A ZA 9705942A ZA 975942 A ZA975942 A ZA 975942A ZA 975942 B ZA975942 B ZA 975942B
Authority
ZA
South Africa
Prior art keywords
peptide formulations
aqueous protic
protic peptide
aqueous
formulations
Prior art date
Application number
ZA9705942A
Other languages
English (en)
Inventor
Cynthia L Stevenson
Sally A Tao
Steven J Prestrelski
James B Eckenhoff
Jeremy C Wright
Joe Leonard
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ZA975942B publication Critical patent/ZA975942B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ZA9705942A 1996-07-03 1997-07-03 Non-aqueous protic peptide formulations. ZA975942B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2112996P 1996-07-03 1996-07-03

Publications (1)

Publication Number Publication Date
ZA975942B true ZA975942B (en) 1998-04-16

Family

ID=21802501

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705942A ZA975942B (en) 1996-07-03 1997-07-03 Non-aqueous protic peptide formulations.

Country Status (27)

Country Link
EP (1) EP0909175B1 (da)
JP (3) JP2001504802A (da)
CN (1) CN1231256C (da)
AR (1) AR008060A1 (da)
AT (1) ATE241997T1 (da)
AU (1) AU737664B2 (da)
BR (1) BR9710130A (da)
CA (1) CA2259403A1 (da)
CO (1) CO4890854A1 (da)
CZ (1) CZ433898A3 (da)
DE (1) DE69722620T2 (da)
DK (1) DK0909175T3 (da)
ES (1) ES2201306T3 (da)
HU (1) HUP9903942A3 (da)
ID (1) ID19165A (da)
IL (1) IL127769A (da)
MY (1) MY121684A (da)
NO (1) NO323933B1 (da)
NZ (1) NZ333580A (da)
PL (1) PL189402B1 (da)
PT (1) PT909175E (da)
RO (1) RO119862B1 (da)
RU (1) RU2203085C2 (da)
SK (1) SK284490B6 (da)
TW (1) TW491703B (da)
WO (1) WO1998000152A1 (da)
ZA (1) ZA975942B (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12627043B2 (en) 2021-03-01 2026-05-12 Stryker Corporation Real time bur chatter compensation in surgical cutting burs

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ433898A3 (cs) * 1996-07-03 1999-04-14 Alza Corporation Nevodné protické peptidové formulace
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004233869B2 (en) * 2003-04-25 2010-08-12 Boston Scientific Scimed, Inc. Solid drug formulation and device for storage and controlled delivery thereof
PT1687019T (pt) * 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AU2013203271B2 (en) * 2007-01-19 2016-05-12 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
CN106389330A (zh) * 2007-01-19 2017-02-15 哈南亚有限公司 用于递送治疗剂的方法和组合物
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
US20120213846A1 (en) 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
HRP20192207T1 (hr) 2010-08-11 2020-02-21 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
US20130288968A1 (en) * 2012-04-30 2013-10-31 Sun Pharmaceutical Industries Ltd. Leuprolide injection
WO2014124096A1 (en) * 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
EP3372224A1 (en) 2017-03-07 2018-09-12 Alrise Biosystems GmbH New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
DE3886880T2 (de) * 1987-10-15 1994-07-14 Syntex Inc Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden.
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
RU2008354C1 (ru) * 1991-03-13 1994-02-28 Данилевич Василий Николаевич Способ хранения препарата протеиназ
JP3756512B2 (ja) * 1992-09-21 2006-03-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 徐放性タンパク質製剤
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JP3597233B2 (ja) * 1993-10-21 2004-12-02 久光製薬株式会社 経鼻組成物及びそれを含有する経鼻製剤
CZ433898A3 (cs) * 1996-07-03 1999-04-14 Alza Corporation Nevodné protické peptidové formulace

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12627043B2 (en) 2021-03-01 2026-05-12 Stryker Corporation Real time bur chatter compensation in surgical cutting burs

Also Published As

Publication number Publication date
CO4890854A1 (es) 2000-02-28
BR9710130A (pt) 1999-08-10
JP2010043105A (ja) 2010-02-25
CN1224356A (zh) 1999-07-28
AU3407397A (en) 1998-01-21
SK179998A3 (en) 1999-05-07
IL127769A (en) 2006-10-31
EP0909175B1 (en) 2003-06-04
CA2259403A1 (en) 1998-01-08
MY121684A (en) 2006-02-28
HUP9903942A2 (hu) 2000-04-28
EP0909175A1 (en) 1999-04-21
HUP9903942A3 (en) 2000-07-28
AU737664B2 (en) 2001-08-30
ATE241997T1 (de) 2003-06-15
PL330869A1 (en) 1999-06-07
RO119862B1 (ro) 2005-05-30
DK0909175T3 (da) 2003-09-29
PL189402B1 (pl) 2005-08-31
CZ433898A3 (cs) 1999-04-14
PT909175E (pt) 2003-10-31
RU2203085C2 (ru) 2003-04-27
ES2201306T3 (es) 2004-03-16
SK284490B6 (sk) 2005-05-05
NO986209L (no) 1998-12-30
NO323933B1 (no) 2007-07-23
DE69722620D1 (de) 2003-07-10
WO1998000152A1 (en) 1998-01-08
IL127769A0 (en) 1999-10-28
TW491703B (en) 2002-06-21
ID19165A (id) 1998-06-28
JP2008195739A (ja) 2008-08-28
DE69722620T2 (de) 2004-04-29
CN1231256C (zh) 2005-12-14
NO986209D0 (no) 1998-12-30
AR008060A1 (es) 1999-12-09
JP2001504802A (ja) 2001-04-10
NZ333580A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
HUP9903942A3 (en) Non-aqueous protic peptide formulations
ZA975941B (en) Non-aqueous polar aprotic peptide formulations.
ZA9710429B (en) Broad-spectrumδ-endotoxins.
GB9627091D0 (en) An inverted E antenna
GB2332660B (en) Improved deflector
ZA972186B (en) Lytic peptides.
ZA97928B (en) Novel heteroaryl-oxazolidinones.
GB2311689B (en) Bandwidth bidding
ZA971466B (en) Endothelin-receptor-antagonists.
GB9720362D0 (en) Python
ZA978477B (en) Cysteine containing peptides.
GB9613705D0 (en) Novel peptides
ZA971474B (en) Endothelin-receptor-antagonists.
ZA975469B (en) X14-mannitol.
ZA979237B (en) Terminal block.
ZA973697B (en) Sprinkler.
GB9612054D0 (en) The spazzle (spacial puzzle)
GB9612648D0 (en) Peptides
SG55039A1 (en) Peptides
GB9608430D0 (en) Peptides
GB9605904D0 (en) Peptides
GB9626362D0 (en) Peptides
GB9625227D0 (en) Peptides
GB9606765D0 (en) Peptides
ZA971534B (en) Peptide derivatives.